Clinical Utility of the Sivelestat for the Treatment of ALI/ARDS: Moving on in the Controversy?

Acute respiratory distress syndrome (ARDS) is a serious condition that can arise following direct or indirect acute lung injury (ALI). It is heterogeneous and has a high mortality rate. Supportive care is the mainstay of treatment and there is no definitive pharmacological treatment as yet. In noncl...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Qiongli, Wang, Yi, Yang, Chunbo, Li, Xiang, Yu, Xiangyou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412801/
https://www.ncbi.nlm.nih.gov/pubmed/36911225
http://dx.doi.org/10.1007/s44231-022-00012-5
_version_ 1784775583577669632
author Ding, Qiongli
Wang, Yi
Yang, Chunbo
Li, Xiang
Yu, Xiangyou
author_facet Ding, Qiongli
Wang, Yi
Yang, Chunbo
Li, Xiang
Yu, Xiangyou
author_sort Ding, Qiongli
collection PubMed
description Acute respiratory distress syndrome (ARDS) is a serious condition that can arise following direct or indirect acute lung injury (ALI). It is heterogeneous and has a high mortality rate. Supportive care is the mainstay of treatment and there is no definitive pharmacological treatment as yet. In nonclinical studies, neutrophil elastase inhibitor sivelestat appears to show benefit in ARDS without inhibiting the host immune defense in cases of infection. In clinical studies, the efficacy of sivelestat in the treatment of ARDS remains controversial. The currently available evidence suggests that sivelestat may show some benefit in the treatment of ARDS, although large, randomized controlled trials are needed in specific pathophysiological conditions to explore these potential benefits.
format Online
Article
Text
id pubmed-9412801
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-94128012022-08-26 Clinical Utility of the Sivelestat for the Treatment of ALI/ARDS: Moving on in the Controversy? Ding, Qiongli Wang, Yi Yang, Chunbo Li, Xiang Yu, Xiangyou Intensive Care Res Commentary Acute respiratory distress syndrome (ARDS) is a serious condition that can arise following direct or indirect acute lung injury (ALI). It is heterogeneous and has a high mortality rate. Supportive care is the mainstay of treatment and there is no definitive pharmacological treatment as yet. In nonclinical studies, neutrophil elastase inhibitor sivelestat appears to show benefit in ARDS without inhibiting the host immune defense in cases of infection. In clinical studies, the efficacy of sivelestat in the treatment of ARDS remains controversial. The currently available evidence suggests that sivelestat may show some benefit in the treatment of ARDS, although large, randomized controlled trials are needed in specific pathophysiological conditions to explore these potential benefits. Springer Netherlands 2022-08-26 2023 /pmc/articles/PMC9412801/ /pubmed/36911225 http://dx.doi.org/10.1007/s44231-022-00012-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Commentary
Ding, Qiongli
Wang, Yi
Yang, Chunbo
Li, Xiang
Yu, Xiangyou
Clinical Utility of the Sivelestat for the Treatment of ALI/ARDS: Moving on in the Controversy?
title Clinical Utility of the Sivelestat for the Treatment of ALI/ARDS: Moving on in the Controversy?
title_full Clinical Utility of the Sivelestat for the Treatment of ALI/ARDS: Moving on in the Controversy?
title_fullStr Clinical Utility of the Sivelestat for the Treatment of ALI/ARDS: Moving on in the Controversy?
title_full_unstemmed Clinical Utility of the Sivelestat for the Treatment of ALI/ARDS: Moving on in the Controversy?
title_short Clinical Utility of the Sivelestat for the Treatment of ALI/ARDS: Moving on in the Controversy?
title_sort clinical utility of the sivelestat for the treatment of ali/ards: moving on in the controversy?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412801/
https://www.ncbi.nlm.nih.gov/pubmed/36911225
http://dx.doi.org/10.1007/s44231-022-00012-5
work_keys_str_mv AT dingqiongli clinicalutilityofthesivelestatforthetreatmentofaliardsmovingoninthecontroversy
AT wangyi clinicalutilityofthesivelestatforthetreatmentofaliardsmovingoninthecontroversy
AT yangchunbo clinicalutilityofthesivelestatforthetreatmentofaliardsmovingoninthecontroversy
AT lixiang clinicalutilityofthesivelestatforthetreatmentofaliardsmovingoninthecontroversy
AT yuxiangyou clinicalutilityofthesivelestatforthetreatmentofaliardsmovingoninthecontroversy

Ejemplares similares